Bullish Case: Vol surface shows lowest ANIK IV near mid strikes (~13–17) with backwardation into Jul–Aug; that pattern fits IV-risk premium unwinding. My May 20 bullish rebound toward 15.5–16.5 hasn’t hit yet (14.59 now), so upside reads as delayed. Oracle: defined-risk call spreads near $15 align with modest mean-reversion if SPY’s IV keeps decaying.

Bearish Case: ANIK return surface concentrates likelihood around small negatives to low positives, with thinner mass above +20% for short holds. ANIK vol stays elevated in the wings, consistent with tail fear. May 20 downside to 13.0–12.5 hasn’t occurred, but risk skews to renewed weakness on catalyst misses. Oracle: bearish puts via spreads around $13 would track that tail; AI forecast is -2.28%.

Potential Outcomes:

1. 38%: $14.0–15.3 range into Jul 17; ATM IV lowest + backwardation mean-reversion.
2. 28%: $12.5–13.8 by late Aug 21 if SPY risk-off lifts put skew/realized vol.
3. 22%: $15.5–16.8 if a positive trial/FDA headline appears before Jul 17 (call IV stops drifting higher).
4. 12%: <$12.5 on adverse clinical/FDA surprise (steep put-IV spike; failed support).

June 24, 2026